vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and CEVA INC (CEVA). Click either name above to swap in a different company.

Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $31.3M, roughly 1.4× CEVA INC). CEVA INC runs the higher net margin — -3.5% vs -23.3%, a 19.8% gap on every dollar of revenue. On growth, CEVA INC posted the faster year-over-year revenue change (7.1% vs 7.0%). Over the past eight quarters, CEVA INC's revenue compounded faster (19.1% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

CEVA Logistics is a global logistics and supply chain company that operates both freight management and contract logistics. It was purchased by the CMA CGM group in 2019. Since this purchase, CMA CGM has acquired other logistics and transportation companies to merge with and develop CEVA Logistics, such as Ingram Micro Commerce & Lifecycle Services and GEFCO.

AMRN vs CEVA — Head-to-Head

Bigger by revenue
AMRN
AMRN
1.4× larger
AMRN
$45.1M
$31.3M
CEVA
Growing faster (revenue YoY)
CEVA
CEVA
+0.1% gap
CEVA
7.1%
7.0%
AMRN
Higher net margin
CEVA
CEVA
19.8% more per $
CEVA
-3.5%
-23.3%
AMRN
Faster 2-yr revenue CAGR
CEVA
CEVA
Annualised
CEVA
19.1%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
CEVA
CEVA
Revenue
$45.1M
$31.3M
Net Profit
$-10.5M
$-1.1M
Gross Margin
88.1%
Operating Margin
35.5%
-1.3%
Net Margin
-23.3%
-3.5%
Revenue YoY
7.0%
7.1%
Net Profit YoY
33.0%
36.8%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
CEVA
CEVA
Q1 26
$45.1M
Q4 25
$49.2M
$31.3M
Q3 25
$49.7M
$28.4M
Q2 25
$72.7M
$25.7M
Q1 25
$42.0M
$24.2M
Q4 24
$62.3M
$29.2M
Q3 24
$42.3M
$27.2M
Q2 24
$67.5M
$28.4M
Net Profit
AMRN
AMRN
CEVA
CEVA
Q1 26
$-10.5M
Q4 25
$-1.2M
$-1.1M
Q3 25
$-7.7M
$-2.5M
Q2 25
$-14.1M
$-3.7M
Q1 25
$-15.7M
$-3.3M
Q4 24
$-48.6M
$-1.7M
Q3 24
$-25.1M
$-1.3M
Q2 24
$1.5M
$-291.0K
Gross Margin
AMRN
AMRN
CEVA
CEVA
Q1 26
Q4 25
47.1%
88.1%
Q3 25
44.7%
88.0%
Q2 25
69.2%
86.2%
Q1 25
59.8%
85.6%
Q4 24
-15.4%
88.5%
Q3 24
38.5%
85.4%
Q2 24
63.4%
89.7%
Operating Margin
AMRN
AMRN
CEVA
CEVA
Q1 26
35.5%
Q4 25
-12.9%
-1.3%
Q3 25
-22.4%
-7.3%
Q2 25
-22.0%
-17.5%
Q1 25
-39.9%
-18.1%
Q4 24
-84.3%
0.3%
Q3 24
-59.5%
-9.6%
Q2 24
-0.8%
-0.1%
Net Margin
AMRN
AMRN
CEVA
CEVA
Q1 26
-23.3%
Q4 25
-2.5%
-3.5%
Q3 25
-15.6%
-8.8%
Q2 25
-19.4%
-14.4%
Q1 25
-37.4%
-13.7%
Q4 24
-78.0%
-5.9%
Q3 24
-59.4%
-4.8%
Q2 24
2.3%
-1.0%
EPS (diluted)
AMRN
AMRN
CEVA
CEVA
Q1 26
Q4 25
$0.00
Q3 25
$-0.02
Q2 25
$-0.03
Q1 25
$-0.04
Q4 24
$-0.12
Q3 24
$-0.06
Q2 24
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
CEVA
CEVA
Cash + ST InvestmentsLiquidity on hand
$307.8M
$40.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$336.5M
Total Assets
$645.8M
$388.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
CEVA
CEVA
Q1 26
$307.8M
Q4 25
$302.6M
$40.6M
Q3 25
$286.6M
$17.3M
Q2 25
$298.7M
$29.1M
Q1 25
$281.8M
$18.8M
Q4 24
$294.2M
$18.8M
Q3 24
$305.7M
$13.2M
Q2 24
$306.7M
$25.0M
Stockholders' Equity
AMRN
AMRN
CEVA
CEVA
Q1 26
Q4 25
$459.3M
$336.5M
Q3 25
$458.9M
$268.7M
Q2 25
$464.9M
$265.9M
Q1 25
$473.7M
$269.1M
Q4 24
$486.2M
$266.6M
Q3 24
$531.4M
$265.8M
Q2 24
$551.9M
$263.8M
Total Assets
AMRN
AMRN
CEVA
CEVA
Q1 26
$645.8M
Q4 25
$670.8M
$388.3M
Q3 25
$659.8M
$306.0M
Q2 25
$670.1M
$302.8M
Q1 25
$655.7M
$310.0M
Q4 24
$685.3M
$308.9M
Q3 24
$750.6M
$304.9M
Q2 24
$799.9M
$300.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
CEVA
CEVA
Operating Cash FlowLast quarter
$8.7M
Free Cash FlowOCF − Capex
$7.2M
FCF MarginFCF / Revenue
23.1%
Capex IntensityCapex / Revenue
4.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-6.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
CEVA
CEVA
Q1 26
Q4 25
$15.3M
$8.7M
Q3 25
$-12.7M
$-5.9M
Q2 25
$16.6M
$1.2M
Q1 25
$-12.5M
$-7.4M
Q4 24
$-13.3M
$8.0M
Q3 24
$-2.4M
$399.0K
Q2 24
$-2.7M
$2.4M
Free Cash Flow
AMRN
AMRN
CEVA
CEVA
Q1 26
Q4 25
$7.2M
Q3 25
$-6.3M
Q2 25
$492.0K
Q1 25
$-7.7M
Q4 24
$7.0M
Q3 24
$-15.0K
Q2 24
$1.8M
FCF Margin
AMRN
AMRN
CEVA
CEVA
Q1 26
Q4 25
23.1%
Q3 25
-22.1%
Q2 25
1.9%
Q1 25
-31.8%
Q4 24
24.0%
Q3 24
-0.1%
Q2 24
6.2%
Capex Intensity
AMRN
AMRN
CEVA
CEVA
Q1 26
Q4 25
4.8%
Q3 25
1.5%
Q2 25
2.7%
Q1 25
1.3%
Q4 24
3.5%
Q3 24
1.5%
Q2 24
2.1%
Cash Conversion
AMRN
AMRN
CEVA
CEVA
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-1.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

CEVA
CEVA

Transferred At Point In Time$28.1M90%
Transferred Over Time$3.2M10%

Related Comparisons